Literature DB >> 21576510

Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study.

Fang Tang1, Yan Quan, Zhong-Tao Xin, Jens Wrammert, Mai-Juan Ma, Hui Lv, Tian-Bao Wang, Hong Yang, Jan H Richardus, Wei Liu, Wu-Chun Cao.   

Abstract

Six years have passed since the outbreak of severe acute respiratory syndrome (SARS). Previous studies indicated that specific Abs to SARS-related coronavirus (SARS-CoV) waned over time in recovered SARS patients. It is critical to find out whether a potential anamnestic response, as seen with other viral infections, exists to protect a person from reinfection in case of another SARS outbreak. Recovered SARS patients were followed up to 6 y to estimate the longevity of specific Ab. The specific memory B cell and T cell responses to SARS-CoV Ags were measured by means of ELISPOT assay. Factors in relation to humoral and cellular immunity were investigated. Six years postinfection, specific IgG Ab to SARS-CoV became undetectable in 21 of the 23 former patients. No SARS-CoV Ag-specific memory B cell response was detected in either 23 former SARS patients or 22 close contacts of SARS patients. Memory T cell responses to a pool of SARS-CoV S peptides were identified in 14 of 23 (60.9%) recovered SARS patients, whereas there was no such specific response in either close contacts or healthy controls. Patients with more severe clinical manifestations seemed to present a higher level of Ag-specific memory T cell response. SARS-specific IgG Ab may eventually vanish and peripheral memory B cell responses are undetectable in recovered SARS patients. In contrast, specific T cell anamnestic responses can be maintained for at least 6 y. These findings have applications in preparation for the possible reemergence of SARS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21576510     DOI: 10.4049/jimmunol.0903490

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  226 in total

1.  Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses.

Authors:  Jingxian Zhao; Abeer N Alshukairi; Salim A Baharoon; Waleed A Ahmed; Ahmad A Bokhari; Atef M Nehdi; Laila A Layqah; Mohammed G Alghamdi; Manal M Al Gethamy; Ashraf M Dada; Imran Khalid; Mohamad Boujelal; Sameera M Al Johani; Leatrice Vogel; Kanta Subbarao; Ashutosh Mangalam; Chaorong Wu; Patrick Ten Eyck; Stanley Perlman; Jincun Zhao
Journal:  Sci Immunol       Date:  2017-08-04

Review 2.  Practical guidance for clinical laboratories for SARS-CoV-2 serology testing.

Authors:  Carmen Charlton; Jamil Kanji; Vanessa Tran; Julianne Kus; Jonathan Gubbay; Carla Osiowy; Jason Robinson; Inna Sekirov; Michael Drebot; Todd Hatchette; Derek Stein; Nadia El-Gabalawy; Amanda Lang; Lei Jiao; Paul Levett; Heidi Wood; Christian Therrien; L Robbin Lindsay; Muhammad Morshed; Jessica Forbes; Antonia Dibernardo
Journal:  Can Commun Dis Rep       Date:  2021-05-07

Review 3.  Certainty of success: three critical parameters in coronavirus vaccine development.

Authors:  David C Kaslow
Journal:  NPJ Vaccines       Date:  2020-05-25       Impact factor: 7.344

Review 4.  Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models.

Authors:  Yanqun Wang; Jing Sun; Airu Zhu; Jingxian Zhao; Jincun Zhao
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

Review 5.  Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review.

Authors:  Esteban Ortiz-Prado; Katherine Simbaña-Rivera; Lenin Gómez-Barreno; Mario Rubio-Neira; Linda P Guaman; Nikolaos C Kyriakidis; Claire Muslin; Ana María Gómez Jaramillo; Carlos Barba-Ostria; Doménica Cevallos-Robalino; Hugo Sanches-SanMiguel; Luis Unigarro; Rasa Zalakeviciute; Naomi Gadian; Andrés López-Cortés
Journal:  Diagn Microbiol Infect Dis       Date:  2020-05-30       Impact factor: 2.803

6.  Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.

Authors:  Yoshikazu Honda-Okubo; Dale Barnard; Chun Hao Ong; Bi-Hung Peng; Chien-Te Kent Tseng; Nikolai Petrovsky
Journal:  J Virol       Date:  2014-12-17       Impact factor: 5.103

Review 7.  Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.

Authors:  Heeyoun Cho; Jean-Louis Excler; Jerome H Kim; In-Kyu Yoon
Journal:  Hum Vaccin Immunother       Date:  2017-11-29       Impact factor: 3.452

8.  Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection.

Authors:  Rudragouda Channappanavar; Craig Fett; Jincun Zhao; David K Meyerholz; Stanley Perlman
Journal:  J Virol       Date:  2014-07-23       Impact factor: 5.103

Review 9.  The single-cell landscape of immunological responses of CD4+ T cells in HIV versus severe acute respiratory syndrome coronavirus 2.

Authors:  Jack A Collora; Runxia Liu; Kristen Albrecht; Ya-Chi Ho
Journal:  Curr Opin HIV AIDS       Date:  2021-01       Impact factor: 4.283

10.  SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition.

Authors:  Annika Nelde; Tatjana Bilich; Jonas S Heitmann; Yacine Maringer; Helmut R Salih; Malte Roerden; Maren Lübke; Jens Bauer; Jonas Rieth; Marcel Wacker; Andreas Peter; Sebastian Hörber; Bjoern Traenkle; Philipp D Kaiser; Ulrich Rothbauer; Matthias Becker; Daniel Junker; Gérard Krause; Monika Strengert; Nicole Schneiderhan-Marra; Markus F Templin; Thomas O Joos; Daniel J Kowalewski; Vlatka Stos-Zweifel; Michael Fehr; Armin Rabsteyn; Valbona Mirakaj; Julia Karbach; Elke Jäger; Michael Graf; Lena-Christin Gruber; David Rachfalski; Beate Preuß; Ilona Hagelstein; Melanie Märklin; Tamam Bakchoul; Cécile Gouttefangeas; Oliver Kohlbacher; Reinhild Klein; Stefan Stevanović; Hans-Georg Rammensee; Juliane S Walz
Journal:  Nat Immunol       Date:  2020-09-30       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.